First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: Results of the XaNADU-ACS Trial

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 3, 2005, Pages 439-447

  Alexander, J H ^a   Yang, H ^a   Becker, R C ^a   Kodama, K ^b   Goodman, S ^c   Dyke, C K ^b   Kleiman, N S ^d   Hochan, J S ^e   Berger, P B ^a   Cohen, E A ^f   Lincoff, A M ^g   Burton, J R ^h   Bovill, E G ⁱ   Kawai, C ^j   Armstrong, P W ^h   Harrington, R A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b OSAKA POLICE HOSPITAL   (Japan)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e NEW YORK UNIVERSITY   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g LERNER RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ UNIVERSITY OF VERMONT   (United States)

^j TAKEDA GENERAL HOSPITAL   (Japan)

more..

Author keywords

Acute coronary syndromes; Anticoagulant; Clinical trial; Factor Xa inhibitor

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; BLOOD CLOTTING FACTOR 10A; NAPHTHALENE DERIVATIVE; PROPIONIC ACID DERIVATIVE; SERINE PROTEINASE;

ADULT; AGED; BLEEDING; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; REVIEW; ST SEGMENT; UNITED STATES; ACUTE DISEASE; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOSE RESPONSE; DRUG ANTAGONISM; ELECTROCARDIOGRAPHY; ISCHEMIA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; CORONARY ARTERIOSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FACTOR XA; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NAPHTHALENES; PARTIAL THROMBOPLASTIN TIME; PROPIONIC ACIDS; SERINE ENDOPEPTIDASES;

EID: 23944460642     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.01081.x     Document Type: Review

References (23)

1. The American College of Cardiology/American Heart Association Task Force on Practice Guidelines. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. Available at: http://www.acc.org/clinical/guidelines/unstable/ incorporated/index. htm. Accessed 9 December 2003.
2. Hirsh J. Low-molecular-weight heparin: a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation 1998; 98: 1575-82.
3. Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 2003; 289: 331-42.
4. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619-25.
5. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW for the Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated hep-arin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-702.
6. Coussement PK, Bassand JP, Convens C, Vrolix M, Boland J, Grollier G, Michels R, Vahanian A, Vanderheyden M, Rupprecht HJ, Van de Werf F. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: PENTALYSE study. Eur Heart J 2001; 22: 1716-24.
7. Simoons ML. PENTasaccharide in Unstable Angina (PENTUA) Results. Presented at: Late Breaking Clinical Trials, American Heart Association Meetings; November 2001; Anaheim, CA.
8. Vuillemenot A, Schiele F, Meneveau N, Claudel S, Donat F, Fontecave S, Cariou R, Samama MM, Bassand JP. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent-a pilot study in the setting of coronary angioplasty. Thromb Haemost 1999; 81: 214-20.
9. Rezaie AR. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost 2003; 89: 112-21.
10. Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, Lincoff AM, Gerstenblith G, Dzavik V, Gardner LH, Hasselblad V, Zillman LA, Shimoto Y, Robertson TL, Kunitada S, Armstrong PW, Harrington RA. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 2002; 105: 2385-91.
11. Shimbo D, Osende J, Chen J, Robbins J, Shimoto Y, Kunitada S, Fuster V, Badimon JJ. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Thromb Haemost 2002; 88: 733-8.
12. Alexander JH, Becker RC, Yang H, Becker RC, Hasselblad V, Zillman LA, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff AM, Saint-Jacques H, Chetcuti S, Burton JR, Buergler JM, Spence FP, Shimoto Y, Robertson TL, Kunitada S, Bovill EG, Armstrong PW, Harrington RA, on behalf of the XaNADU-PCI PILOT Investigators. Initial experience with the direct factor Xa inhibitor, DX-9065a, in patients undergoing percutaneous coronary intervention: final results of the XaNADU-PCI pilot. J Thromb Haemost 2004; 2: 234.
13. Newby LK, Harrington RA, Bhapkar MV, van de Werf F, Hochman JS, Granger CB, Simes RJ, Davis CG, Topol EJ, Califf RM, Moliterno DJ. An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. J Thromb Thromb 2002; 14: 33-42.
14. Popma JJ, Ohman EM, Weitz J, Lincoff AM, Harrington RA, Berger P. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 2001; 119: 321S-36S.
15. Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW, Topol EJ, Califf RM, Harrington RA. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Am Heart J 2002; 143: 242-8.
16. Gottlieb SO, Weisfeldt ML, Ouyang P, Mellits ED, Gerstenblith G. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med 1986; 314: 1214-9.
17. Langer A, Freeman MR, Armstrong PW. ST segment shift in unstable angina: pathophysiology and association with coronary anatomy and hospital outcome. J Am Coll Cardiol 1989; 13: 1495-502.
18. Cohn PF, Fox KM, Daly C. Silent myocardial ischemia. Circulation 2003; 108: 1263-77.
19. Goodman SG, Barr A, Sobtchouk A, Cohen M, Fromell GJ, Laperriere L, Hill C, Langer A. Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. J Am Coll Cardiol 2000; 36: 1507-13.
20. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A for the INTERACT Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein Ilb/IIIa inhibitor eptifibatide. Circulation 2003; 107: 238-44.
21. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yock PG, Anderson HV, Nygaard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashears L, Gerstenblith G. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 1996; 94: 2083-9.
22. Jernberg T, Abrahamsson P, Lindahl B, Johanson P, Wallentin L, Dellborg M. Continuous multilead ST-monitoring identifies patients with unstable coronary artery disease who benefit from extended antithrombotic treatment. Eur Heart J 2002; 23: 1093-101.
23. Alexander JH, Becker RC, Hasselblad V, Dyke CK, Robertson TL, Harrington RA, Bovill EG. Effect of the direct factor Xa inhibitor, DX-9065a, on thrombin generation in patients with stable coronary artery disease. J Thromb Haemost 2003; 1 (Suppl. 1): P2017.